| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802289614026 | 228961402 | NEORECORMON INJ.SO.PFS 5000 IU/0,3MLPREF.SY BTx6PREF.SYR.x0,3ML | 172.94 | 181.41 | 219.22 |
| 05/2018 | 2802289615023 | 228961502 | NEORECORMON INJ.SO.PFS 10000 IU/0,6MLPREF.S BTx6 PREF.SYR.x0,6ML | 315.13 | 319.86 | 372.96 |
| 05/2018 | 2802289620027 | 228962002 | NEORECORMON INJ.SO.PFS 30.000IU/0,6ML PREF.SY BTx4PF.SYR.x0,6ML | 715.94 | 726.68 | 820.34 |
For treatment of anemia (from renal transplants or certain HIV treatment)
Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.
* 20.2 +/- 15.9 mL/h/kg [150 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy] * 23.6 +/- 9.5 mL/h/kg [150 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy] * 9.2 +/- 4.7 mL/h/kg [40,000 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy] * 13.9 +/- 7.6 mL/h/kg [40,000 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]